Clinical Trial: A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors

U.S., May 29 -- ClinicalTrials.gov registry received information related to the study (NCT06993116) titled 'A Phase I Study of SHR-4712 in Patients With Advanced Solid Tumors' on May 19.

Brief Summary: This is a Phase 1, open label, first-in-human study to evaluate safety, tolerability, Pharmacokinetics (PK), Pharmacodynamics (PD), immunogenicity and anti-tumor activity of SHR-4712 in patients with advanced solid tumors. Patients will treat with SHR-4712 until unacceptable toxicity or disease progression.

Study Start Date: June, 2025

Study Type: INTERVENTIONAL

Condition: Advanced Solid Tumor

Intervention: DRUG: SHR-4712 Injection

SHR-4712 injection.

Recruitment Status: NOT_YET_RECRUITING

Sponsor: Guangdong Hengrui Pharmaceutical C...